CID Vascular Sponsors Tech News & Trends at Euro PCR 2010

PARIS, May 26, 2010 – CID Vascular, a leader in interventional medicine, is sponsoring Tech
News & Trends at Euro PCR on May 26th in Paris. The two-hour session will
explore issues surrounding the complex decisions doctors must make when
implanting coronary stents in patients with conditions that affect blood
clotting.

Two live cases performed [...]

For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System

InspireMD is Also Proud to Announce That MGuard(TM) is Now Available With an Improved Delivery System

PARIS, May 26, 2010 – InspireMD, Ltd. announced today the next generation MGuard stent,
MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard
Prime(R) offers an advanced patented Cobalt Chromium design, superior
flexibility and excellent deliverability on top of the established [...]

Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System

Randomized Study of Nearly 3,000 Patients to Evaluate Company's Third-Generation Drug-Eluting Stent Technology

NATICK, Massachussetts, May 26, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced the
initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored
research (ISR) study designed to compare the performance of the PROMUS(R)
Element(TM) Everolimus-Eluting Coronary Stent System to the XIENCE PRIME(TM)
Everolimus-Eluting Coronary Stent [...]

Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States

Company Supplements Broad RNAi IP Portfolio and Strengthens Growing Position in Oncology

LONDON, May 26, 2010 – Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company")
announces the issuance of United States patent 7,723,316, titled Compositions
and Methods of RNAi Therapeutics For Treatment of Cancer and Other
Neovascularization Disease, by the United States Patent and Trademark Office
(USPTO). The [...]

First Coronary Stent on Drug Eluting Balloon Implanted

Innovation Improves Patient's Comfort and Reduces Procedure Cost Significantly

HELMOND, The Netherlands, May 25, 2010 – Blue Medical today announced a major step forward in its quest to improve
the quality of life of patients with cardiovascular disease, with the start
of the PIONEER trial, in which a new safe concept of stent-drug combination
is evaluated.
[...]

Cancer Detection at Your Fingertips: Bioholo-tomography Promises Enormous Growth Potential, According to Frost & Sullivan

LONDON, May 25, 2010 – As the potential cancer population increases, an effective long-term
solution for early cancer detection needs to be found. In some areas of the
world, cancer incidence is growing by 3 per cent per annum, and the cost of
cancer care is a ticking time bomb for global healthcare expenditure.

[...]

Philips Unveils Concepts of Future Living to Launch Livable Cities Awards

AMSTERDAM, May 25, 2010 – Royal Philips Electronics (NYSE: PHG, AEX: PHI) today gave a glimpse of
what our future living environments could be like with the unveiling of three
concepts – 'Healing Bed', 'Air Tree' and 'Soundbarrier'. All three concepts
aim to reconnect us with the natural environment, an increasingly rare
commodity in a today's urbanized world. [...]

Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers

CALGARY, Canada, May 25, 2010 – Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC,
NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3
trial examining REOLYSIN in combination with paclitaxel and carboplatin in
patients with platinum-refractory head and neck cancers. The Company had
previously received approval from the U.S. Food and Drug Administration (FDA)
under the Special Protocol Assessment [...]

Abbott’s Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves

Preliminary Results Also Show MitraClip Device Maintains Durability through Two Years in Patients Treated for Mitral Regurgitation

PARIS, May 25, 2010 – Abbott (NYSE: ABT) today announced new data from the landmark EVEREST II
(Endovascular Valve Edge-to-Edge REpair STudy) trial, which provide
additional details about the safety and clinical benefit of Abbott's
investigational MitraClip(R) system for the two [...]

New Data Reinforces Safety Profile of Abbott’s Market-Leading XIENCE V(R) Drug Eluting Stent

In XIENCE V USA Study, XIENCE V Demonstrates Low Blood Clot Rate at One Year in Real-World Patient Population

PARIS, May 25, 2010 – Two late-breaking clinical trials presented today at the EuroPCR 2010
conference reinforced the outstanding clinical data supporting Abbott's
market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. In the
XIENCE V USA study of more [...]

NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data

NEVO(TM), Incorporating RES TECHNOLOGY(TM), Continues to Support Excellent Safety and Efficacy Outcomes vs. the Taxus(R) Liberte(R) According to Data Presented at EuroPCR 2010

PARIS, May 25, 2010 – At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued
to demonstrate excellent safety and efficacy outcomes compared to Taxus(R)
Liberte(R) according to new data presented today from the [...]

Edwards SAPIEN Transcatheter Heart Valve Shows Positive One-Year Outcomes in Rigorous Post-Market Study

PARIS, May 25, 2010 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the
science of heart valves and hemodynamic monitoring, today announced that
Martyn Thomas, M.D., reported that the Edwards SAPIEN transcatheter heart
valve demonstrated promising one-year mortality rates for high-risk patients,
many of whom were too sick to undergo traditional open-heart surgery. The
1,038-patient SOURCE Registry [...]

Spa & Resort/Medical Aesthetics Conference and Expo to Be Held September 28-29, 2010

Premier Event for Beauty Care, Skin Care and Spa Professionals Returns to New York

NEW YORK, May 25, 2010 – The Spa & Resort/Medical Aesthetics Conference and Expo
(www.spaandresortexpo.com) will return to New York this fall to educate,
inspire, and empower beauty, skin care, and wellness professionals. The
two-day trade show will take place from September 28-29, 2010 [...]

Abbott’s Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results

New Six-Month Data on Abbott's Bioresorbable Vascular Scaffold Reinforces Its Potential to Be the Next Revolution in Interventional Cardiology

PARIS, May 25, 2010 – Abbott (NYSE: ABT) today announced positive six-month results from the
first 45 patients enrolled in the second stage of the ABSORB trial, which was
presented during the Late-Breaking Clinical Trials session at the [...]

Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)

CAMBRIDGE, England, May 25, 2010 – Executives from Heptares Therapeutics (Welwyn Garden City, UK)
and O2h (Cambridge, UK) announced today an extension of the agreement under
which O2h provides multi-FTE -synthetic chemistry services to support
discovery programmes at Heptares.

Dr. Miles Congreve, Head of Chemistry said, "We are happy to have signed
this new contract [...]

First Major Survey of Multiple Sclerosis (MS) Nurses Highlights Significant Disparities in MS Nursing Across Europe

The Findings from MS-NEED (Multiple Sclerosis-Nurse Empowering EDucation): European Survey Highlights the Need to Define and Benchmark Healthcare Provision in MS Across Europe

BRUSSELS, May 26, 2010 – The first major survey of European Multiple Sclerosis (MS) nurses
revealed that nearly one in three nurses (31%) reported that standards of
MS care are not adequately maintained in [...]